{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:02:09Z","timestamp":1794085329123,"version":"4.8.0"},"reference-count":59,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Special Program Molecular Clinical Oncology-Extens"],"award-info":[{"award-number":["Special Program Molecular Clinical Oncology-Extens"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>BCR\/ABL1<\/jats:italic>\n                    \u2013like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B\u2010lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is characterized by a peculiar transcriptional profile that resembles that of true\n                    <jats:italic>BCR\/ABL1<\/jats:italic>\n                    \u2013positive cases, and have a heterogeneous genetic background and a poor outcome. Next\u2010generation sequencing studies have demonstrated that the majority of patients carry rearrangements of tyrosine kinases or cytokine receptors and mutations of janus kinase (JAK)\/signal transducer and activator of transcription (STAT), thus opening the way to the possible use of targeted therapeutic approaches. However, several issues remain unresolved at both the diagnostic and therapeutic level, such as the definition of a standardized method to identify\n                    <jats:italic>BCR\/ABL1<\/jats:italic>\n                    \u2013like ALL and the design of\n                    <jats:italic>ad hoc<\/jats:italic>\n                    clinical trials examining tyrosine kinase inhibitors or other tailored treatments. These aspects are discussed in this review.\n                  <\/jats:p>","DOI":"10.1002\/cncr.31848","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T10:54:55Z","timestamp":1545130495000},"page":"194-204","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["<i>BCR\/ABL1<\/i>\n                    \u2013like acute lymphoblastic leukemia: How to diagnose and treat?"],"prefix":"10.1002","volume":"125","author":[{"given":"Sabina","family":"Chiaretti","sequence":"first","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine \u201cSapienza\u201d University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-4766","authenticated-orcid":false,"given":"Monica","family":"Messina","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine \u201cSapienza\u201d University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine \u201cSapienza\u201d University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"e_1_2_5_2_1","volume-title":"SEER Cancer Statistics Review, 1975\u20132014","author":"Howlader N","year":"2017"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4938"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2165"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0073"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136366"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726588"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.375"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15251"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0811761106"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239681"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0338"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124941"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.012"},{"key":"e_1_2_5_20_1","doi-asserted-by":"crossref","unstructured":"HarveyRC KangH RobertsKG et al.Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B\u2010precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome\u2013like (\u201cPh\u2010like\u201d or \u201cBCR\u2010ABL1\u2013like\u201d) signature for therapeutic targeting and clinical intervention. Presented at:American Society of Hematology (ASH) 55th Annual Meeting; December 7\u201310 2013;New Orleans LA.","DOI":"10.1182\/blood.V122.21.826.826"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162925"},{"key":"e_1_2_5_22_1","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high\u2010risk B\u2010ALL: a study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi SC","year":"2017","journal-title":"Blood"},{"key":"e_1_2_5_23_1","unstructured":"FasanA KernW NadarajahN et al.Three steps to the diagnosis of adult Ph\u2010like ALL. Presented at:American Society of Hematology (ASH) 57th Annual Meeting; December 5\u20138 2015;Orlando FL."},{"key":"e_1_2_5_24_1","unstructured":"JainN JabbourEJ McKayPZ et al.Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed\/refractory Philadelphia (Ph)\u2010like acute lymphoblastic leukemia: a phase I\u2010II trial. Presented at:American Society of Hematology (ASH) 59th Annual Meeting; December 9\u201312 2017;Atlanta GA."},{"key":"e_1_2_5_25_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph\u2010like ALL in NCI standard\u2010risk patients: a report from the Children\u2019s Oncology Group","volume":"132","author":"Roberts KG","year":"2018","journal-title":"Blood"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4105"},{"key":"e_1_2_5_28_1","unstructured":"ChiarettiS MessinaM LaurettiA et al.Prognostic impact of the BCR\/ABL1\u2010like signature in adult B\u2010lineage ALL. First analysis of the GIMEMA LAL1913 protocol. Presented at23rd Congress of the European Hematology Association; June 14\u201317 2018;Stockholm Sweden."},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.005"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3907"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-256131"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911726107"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.11.018"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.469"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07552.x"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-235408"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.3242"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22439"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529685"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462358"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.013"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13492"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.28"},{"key":"e_1_2_5_44_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/bloodadvances.2017014704","article-title":"Prognostic impact of kinase\u2010activating fusions and IKZF1 deletions in pediatric high\u2010risk B\u2010lineage acute lymphoblastic leukemia","volume":"2","author":"Tran TH","year":"2018","journal-title":"Blood Adv"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-707653"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6408"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.075432"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13342"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14721"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3617"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.6770"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095372"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.13"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139568"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.160531"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415448"},{"key":"e_1_2_5_57_1","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.18632\/oncotarget.24261","article-title":"Inhibition of mTORC1\/C2 signaling improves antileukemia efficacy of JAK\/STAT blockade in CRLF2 rearranged and\/or JAK driven Philadelphia chromosome\u2013like acute B\u2010cell lymphoblastic leukemia","volume":"9","author":"Zhang Q","year":"2018","journal-title":"Oncotarget"},{"key":"e_1_2_5_58_1","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL\u2010class and JAK\u2010STAT activating kinase alterations in Ph\u2010like ALL","volume":"1","author":"Roberts KG","year":"2017","journal-title":"Blood Adv"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21027"},{"key":"e_1_2_5_60_1","article-title":"New approaches to the management of adult acute lymphoblastic leukemia [published online ahead of print September 21, 2018]","author":"Bassan R","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:54:20Z","timestamp":1761868460000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1,15]]}},"alternative-id":["10.1002\/cncr.31848"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31848","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"2018-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}